Screening
other options first. High content is only used for secondary screens to show the compound does what it should do in the cell. HCS is important in target discovery. We have just started to use it for some primary screening but it is hard to judge the benefit as of yet. We use HCS to have additional approaches, additional to the target-based approach. We were recently considering acquiring additional capabilities but we made a strategic decision to use what we have, so now if we want a different approach to a target, HCS is the way we will handle it.”
Overcoming barriers In HighTech Business Decisions’ study, the HTS directors discussed the steps they or their suppli- ers have taken to overcome the barriers to adopt- ing HCS. Most HTS directors noted improve- ments in both software and hardware. On the software side, most HTS directors have seen improvements in both data management and ana- lytical methods. On the hardware side, the HTS directors note major improvements in the usabil- ity of the equipment and higher screening throughputs. A summary of the steps taken to overcome the barriers to adopting HCS is shown in Table 1.
Flexible Single to Multichannel Pipetting CyBi® -FeliX
» Compact liquid handling platform with 12 positions on smallest footprint (650 x 450 mm)
» Reliable precision supports your application in columns, rows, tubes and complete 96/384- well microplates
» Enhanced format flexibility within each pipetting head
» CHOICE™ pipetting head for extensive volume range of 500 nl - 1 ml
Liquid Handling. Automation. Service.
info@cybio-ag.com www.cybio-ag.com
BRAND OF 54
The industry continues to demand improve- ments in HCS, and suppliers are working to pro- vide new tools that will further reduce the barriers to adoption of HCS for drug discovery. These improvements encompass equipment, data man- agement and consumables.
For example, Molecular Devices introduced the ImageXpress® Micro XL Widefield System. This new instrument is equipped with a sCMOS camera offering three times the image capture area. “The increase in field-of-view translates to fewer images needed per well and faster imaging speed, said Dr Grischa Chandy, Product Manager, Cellular Imaging at Molecular Devices. “In addition, the system provides a stable solid-state light source plus environmental control and fluidics options, delivering a robust platform that meets the high throughput demands of a screening laboratory.” Similarly, Thermo Fisher Scientific is looking at new technologies in hardware, software and in informatics which address the coming trends and current bottlenecks in HCS. “We are look- ing at how to make software more automated and easier to use, but maintain the flexibility and power that High Content can provide,” said Scott Keefer, Manager, Product Management, Cellular Imaging Analysis at Thermo Fisher Scientific. “We are also focused on providing the
Drug Discovery World Spring 2013
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80